Borrowing, number of loan agreement Borrowing, Number Of Loan Agreement Borrowing, Number Of Loan Agreement Elements which will be reclassified in the consolidated statement of income (loss) Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Contract liabilities at beginning of period Contract liabilities at end of period Contract liabilities Financial assets, fair value Financial assets, at fair value Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [line items] Deferred tax liabilities / Deferred revenue Contract Liabilities [Member] Contract Liabilities Paid Interests on financial liabilities Interest expense Statistical Measurement [Domain] Statistical Measurement [Domain] Acquisition of property and equipment, net Purchase of property, plant and equipment, classified as investing activities AGA Management 2016-1 AGA Management 2016-1 [Member] This member stands for AGA Management 2016-1. Deferred tax assets / Tax losses carryforwards Unused tax losses [member] AGA Employees 2018 AGA Employees 2018 [Member] Related to the plan. Service cost Increase in net defined benefit liability (asset) resulting from current service cost Operating expenses Operating expense Allocation of prior period income (loss) Increase (decrease) through appropriation of retained earnings, equity Classes of share capital [axis] Classes of share capital [axis] Borrowing, maturity Borrowing, Maturity Borrowing, Maturity Allowance for retirement defined benefit Retirement Defined Benefit [Member] This member stands for retirement defined benefit. From 2nd to 3th year included Later than two years and not later than three years [member] Total shareholders’ equity Balance at beginning of period Balance at end of period Total shareholders’ equity Equity Unused tax losses subject to expiration Unused Tax Losses Subject To Expiration The amount of unused tax losses subject to expiration. Financial liabilities—current portion Financial Liabilities, Current Portion [Member] This member stands for financial liabilities—current portion. AGA Perf Management 2025-2 AGA Perf Management 2025-2 [Member] AGA Perf Management 2025-2 Financial liabilities Financial Liabilities, Trade Payables And Others The amount of financial liabilities, trade payables and others. Net financial income (loss) Finance income (cost) Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) Number of other equity instruments exercised or vested in share-based payment arrangement Additions Increase Through Performance Obligation Being Satisfied, Contract Liabilities The increase in contract liabilities resulting from additions. Non-current financial assets Non-current Financial Assets [Member] This member stands for non-current financial assets. AGA New members 2024-1 AGA New Members 2024-1 [Member] AGA New Members 2024-1 Statement of comprehensive income [abstract] Statement of changes in equity [line items] Statement of changes in equity [line items] Unrealized gains on financial assets Change In Valuation Allowance Of Financial Instruments Types of contracts [domain] Types of contracts [domain] Items which will not reclassified in the consolidated statement of income (loss) Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Grant Income from government grants Disclosure of detailed information about property, plant and equipment [Line Items] Disclosure of detailed information about property, plant and equipment [line items] Net income (loss) Retained earnings, profit (loss) for reporting period Tax Credit Retentions 2023, CIR Tax Credit Retentions 2023, CIR Tax Credit Retentions 2023, CIR Non-current financial assets Non-Current Financial Assets [Abstract] Non-Current Financial Assets Number of target options Number Of Target Options Number Of Target Options Agreement with Sanofi, 2016 Agreement with Sanofi, 2016 Agreement Related To IPH6101 With Sanofi [Member] Agreement Related To IPH6101 With Sanofi Cash, cash equivalents and short-term investments Cash, Cash Equivalents And Short-Term Investments, Assets Cash, Cash Equivalents And Short-Term Investments, Assets Disclosure of non-adjusting events after reporting period [abstract] Disclosure of non-adjusting events after reporting period [abstract] AGA Perf Management 2023-1 AGA Perf Management 2023-1 [Member] AGA Perf Management 2023-1 Financial assets at fair value through profit or loss, category Financial assets at fair value through profit or loss, category [member] BSA 2015-1 BSA 2015-1 [Member] This member stands for BSA 2015-1. Exercise and subscription of equity instruments Exercise And Subscription Of Equity Instruments The increase (decrease) in equity resulting from exercise and subscription of equity instruments. Statement of financial position [abstract] Marketing, communication and public relations Sales and marketing expense Other income and (expenses), net Other operating income (expense) Operating expenses Disclosure of expenses [text block] AGA Bonus 2022-1 AGA Bonus 2022-1 [Member] AGA Bonus 2022-1 Change in provision for charges Adjustments for provisions Cover [Abstract] Maximum Maximum [Member] Short-term investments Financial Assets, Short-Term Investments [Member] Financial Assets, Short-Term Investments Borrowing, maturity, extension period option Borrowing, Maturity, Extension Period Option Borrowing, Maturity, Extension Period Option Sanofi-Aventis Sanofi-Aventis [Member] Sanofi-Aventis Total current liabilities Current liabilities AGA Bonus 2019-1 AGA Bonus 2019-1 [Member] Related to AGA bonus 2019-1. Company Information [Abstract] Company Information BSA 2013 BSA 2013 [Member] This member stands for BSA 2013. Deferred tax asset Deferred tax assets Financial covenant capital risk margin, percentage Financial Covenant Capital Risk Margin, Percentage Financial Covenant Capital Risk Margin, Percentage Nearterm development milestone payments eligible NearTerm Development Milestone Payments Eligible NearTerm Development Milestone Payments Eligible Share premium Share premium BSA 2022-1 BSA 2022-1 [Member] BSA 2022-1 Total Contract liabilities [abstract] Classes of liabilities [domain] Classes of liabilities [domain] Capital increase Capital Increase [Member] Capital Increase Actuarial (gain) / loss Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income Preclinical Services Preclinical Services [Member] Preclinical Services Total comprehensive income (loss) Comprehensive income Statement of changes in equity [abstract] 2014 Monalizumab (NKG2A) agreement with Novo Nordisk Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member] This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement. Security interest on pledge of financial instruments released Security Interest On Pledge Of Financial Instruments Released The values of security interest on the pledge of financial instruments will be released in 2024. AGAP Management 2017-1 AGAP Management 2017-1 [Member] Related to a plan. Disclosure of net defined benefit liability (asset) Disclosure of net defined benefit liability (asset) [text block] Basis of preparation Disclosure of basis of preparation of financial statements [text block] Net receivables (liabilities) Net Amounts Receivable (Payable) Related Party Transactions The net amounts of receivables (payable) resulting from related party transactions. Disclosure of detailed information about financial instruments [line items] Disclosure of detailed information about financial instruments [line items] Document Fiscal Period Focus Document Fiscal Period Focus Total assets Assets Number of free shares granted (in shares) Number of other equity instruments Number of other equity instruments granted in share-based payment arrangement Deferred tax liabilities / Lease contract (IFRS 16 application) Lease Contract [Member] Lease Contract Trade receivables and others - current and non-current portion (excluding receivables related to Property & equipment), variance Adjustments for decrease (increase) in trade and other receivables Number of other equity instruments outstanding in share-based payment arrangement (in shares) Number of other equity instruments outstanding in share-based payment arrangement Lease liabilities – Building "Le Virage" Lease Financing Obligations, Building, "Le Virage" [Member] Related to the finance lease obligations for the "Le Virage" building. Disclosure of variance of deferred revenue Disclosure Of Variance Of Deferred Revenue [Table Text Block] The disclosure of variance of deferred revenue. The 2016 free preferred shares The 2016 Free Preferred Shares [Member] Related to the 2016 free preferred shares. Non-current research tax credit, 2025 Non-Current Research Tax Credit, 2025 Non-Current Research Tax Credit, 2025 Receivables Amounts receivable, related party transactions AGA New Members 2017-1 AGA New Members 2017-1 [Member] This member stands for AGA New Members 2017-1. Types of interest rates [axis] Types of interest rates [axis] Interest paid, classified as operating activities Interest paid, classified as operating activities Regulatory and commercial milestone payments eligible Regulatory And Commercial Milestone Payments Eligible Regulatory And Commercial Milestone Payments Eligible Geographical [Domain] Geographical [Domain] Loan agreement, collateral Loan Agreement Collateral The value of collateral in connection with the loan agreement. Revenue and other income Revenue Advance received - exclusive license Revenue From Contracts With Customers, Advance Payment Received, Licenses The cash outflow for licenses. Disclosure of financial liabilities [Table] Disclosure of financial liabilities [table] Exchange rate variation (non cash) Increase (Decrease) Through Foreign Exchange, Financial Liabilities Increase (Decrease) Through Foreign Exchange, Financial Liabilities Share capital Issued capital [member] Classes of other provisions [domain] Classes of other provisions [domain] Subcontracting costs Subcontracting Costs The amount of subcontracting costs. Transfer from / (to) collaboration liabilities Transfer From / (To) Collaboration Current Liabilities Transfer From / (To) Collaboration Current Liabilities Reversal of provisions for cost of restructuring Reversal of provisions for cost of restructuring 2015 monalizumab agreement, with AstraZeneca 2015 AstraZeneca Monalizumab Agreements [Member] This member stands for 2015 AstraZeneca monalizumab agreements. Disclosure of operating expenses [Table] Disclosure of operating expenses [Table] Disclosure of operating expenses [Table] G&A Selling, general and administrative expense [member] State guaranteed loan BNP Paribas PGE Loan Agreement, BNP Paribas [Member] PGE Loan Agreement, BNP Paribas Deductions Decrease Through Repayments, Current Contract Liabilities Decrease Through Repayments, Current Contract Liabilities Net collection (payments) Net Cash Advance Received From (Made To) Related Parties Net Cash Advance Received From (Made To) Related Parties Purchase of other assets Purchase of other long-term assets, classified as investing activities R&D Research And Development [Member] Research And Development Intangible assets Intangible assets other than goodwill Intangible assets other than goodwill Research tax credit Income From Research Tax Credit The amount of income related to research tax credit. Non-current financial assets, acquisitions Non-current Financial Assets, Acquisitions The increase in non-current financial assets resulting from origination or purchase. Other comprehensive income Accumulated other comprehensive income [member] Disclosure of trade receivables and others Disclosure Of Trade Receivables And Other [Table Text Block] The disclosure of trade receivables and other. Cash and cash equivalents Cash and cash equivalents at the beginning of the year: Cash and cash equivalents at the end of the six-months period: Cash and cash equivalents Other non-current assets Other non-current non-financial assets Prepaid expenses Current prepaid expenses Current prepaid expenses In progress Construction in progress [member] Research activities performance period Research Activities Performance Period Research Activities Performance Period Disclosure of non-adjusting events after reporting period [line items] Disclosure of non-adjusting events after reporting period [line items] Assets Assets [abstract] AGAP Management 2020-1 AGAP Management 2020-1 [Member] AGAP Management 2020-1 Employee departure compensation Employee Departure Compensation [Member] Employee Departure Compensation Right-of-use assets Right-of-use assets [member] Deferred Revenue And Collaboration Liabilities [Roll Forward] Deferred Revenue And Collaboration Liabilities [Roll Forward] Deferred Revenue And Collaboration Liabilities Disclosure of transactions between related parties Disclosure of transactions between related parties [text block] Total liabilities and shareholders’ equity Equity and liabilities Deferred tax assets / Tax losses carry forwards - US UNITED STATES Property, plant and equipment [abstract] Transfer from / (to) collaboration liabilities Transfer To (From) Collaboration Non Current Liabilities Transfer To (From) Collaboration Non Current Liabilities Retained earnings Retained earnings, excluding profit (loss) for reporting period Provisions Provisions AGAP Employees 2021-1 AGAP Employees 2021-1 [Member] AGAP Employees 2021-1 Lands and buildings Land and buildings [member] Current assets Current assets [abstract] Disclosure of change in deferred revenue and collaboration liabilities Explanation of significant changes in contract assets and contract liabilities [text block] Other payables Other current payables Non-current assets Non-current assets [abstract] SICAV and mutual funds SICAV And Mutual Funds [Member] SICAV And Mutual Funds Provisions for employee benefits Provisions For Employee Benefits [Member] Provisions For Employee Benefits Acquisitions Additions other than through business combinations, property, plant and equipment including right-of-use assets General and administrative expenses General and administrative expense Number of mutual funds in which the entity is holding shares Number Of Mutual Funds In Which the Entity is Holding Shares Number Of Mutual Funds In Which the Entity is Holding Shares Income tax / (expense) Disclosure of income tax [text block] Cost of supplies and consumable materials Raw materials and consumables used Security interest on pledge of financial instruments will be released in 2031 Security Interest On Pledge Of Financial Instruments Will Be Released In 2031 The values of Security interest on pledge of financial instruments will be released in 2024. Prepaid expenses Non-Current Prepaid Expenses Non-Current Prepaid Expenses Disclosure of maturity analysis for non-derivative financial liabilities Disclosure of maturity analysis for non-derivative financial liabilities [text block] Income (Loss) Per Share [Abstract] Non-cancellable off-balance sheet purchase commitments Non Cancellable Off Balance Sheet Purchased Commitments Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date. Stock Options 2020-1 Stock Options 2020-1 [Member] Stock Options 2020-1 Foreign exchange losses Foreign exchange loss AGA Bonus 2021-1 AGA Bonus 2021-1 [Member] AGA Bonus 2021-1 Cash, cash equivalents and financial assets Cash, cash equivalents and financial assets Total Cash, Cash Equivalents And Financial Assets The amount of cash, cash equivalents and financial assets. AGA Perf Management 2022-1 AGA Perf Management 2022-1 [Member] AGA Perf Management 2022-1 Total, acquisitions Total, Acquisitions The increase in short-term investments and non-current financial assets resulting from origination or purchase. Security interest on pledge of financial instruments will be released in 2027 Security Interest On Pledge Of Financial Instruments Will Be Released In 2027 The values of security interest on pledge of financial instruments will be released in 2027. Security interest on pledge of financial instruments will be released in 2024 Security Interest On Pledge Of Financial Instruments Will Be Released In 2024 The values of security interest on the pledge of financial instruments will be released in 2024. Risk profile rate Risk Profile Rate Risk Profile Rate Related party transactions [abstract] Categories of financial liabilities Categories of financial liabilities [domain] Over 5 years Later than five years [member] Other purchases and external expenses Other Purchases And External Expenses The amount of other purchases and external expenses. Personnel expenses other than share-based compensation Personnel expenses other than share-based compensation Short-term employee benefits expense Related party transactions Disclosure of related party [text block] Classes of financial assets [domain] Classes of financial assets [domain] Adjustment for share instruments (in shares) Dilutive effect of convertible instruments on weighted average number of ordinary shares Intangible assets Disclosure of intangible assets [text block] AGAP Employees 2020-1 AGAP Employees 2020-1 [Member] AGAP Employees 2020-1 Types of financial assets Types of financial assets [domain] Non-scientific advisory and consulting Non-scientific Advisory And Consulting The amount of non-scientific advisory and consulting. Lease liabilities - Meraki Lease Financing Obligations, Meraki [Member] Lease Financing Obligations, Meraki VAT refund Current value added tax receivables Exercise and subscription of equity instruments (in shares) Exercise And Subscription Of Equity Instruments, In Shares The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments. Disposals Disposals, property, plant and equipment including right-of-use assets Repayments of borrowings/leases liabilities Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities Use of judgments and estimates Disclosure of accounting judgements and estimates [text block] Other agreement Other Agreements [Member] This member stands for other agreement. Disclosure of financial liabilities per maturity Disclosure Of Financial Liabilities Per Maturity [Table Text Block] The disclosure of financial liabilities per maturity. Shared-based payment Increase (decrease) through share-based payment transactions, equity Trade payables and others (excluding payables related to capital expenditures) Trade and other payables Disclosure of classes of share capital [Table] Disclosure of classes of share capital [table] Foreign currency translation gain (loss) Foreign currency translation loss Other comprehensive income, net of tax, exchange differences on translation of foreign operations Collaboration liabilities – current portion Collaboration Liabilities, Current The amount of current collaboration liabilities. Total non-current assets Non-current assets Trade payables and others (excluding payables related to capital expenditures) Current Trade Payables And Others Excluding Payables Related To Capital Expenditures The amount of current Trade payables and others, excluding payables related to capital expenditures. Disclosure of defined benefit plans [table] Disclosure of defined benefit plans [table] Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Classes of property, plant and equipment [domain] Classes of property, plant and equipment [domain] Milestone payment received - option exercised Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised Trade receivables and others Disclosure of trade and other receivables [text block] Effect of the exchange rate changes Effect of exchange rate changes on cash and cash equivalents Translation of transactions denominated in foreign currency Description of accounting policy for foreign currency translation [text block] BSAAR 2015 BSAAR 2015 [Member] This member stands for BSAAR 2015. Net cash generated from / (used in) operating activities: Cash flows from (used in) operating activities Number of other equity instruments forfeited in share-based payment arrangement (in shares) Number of other equity instruments forfeited in share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [Line Items] Disclosure of terms and conditions of share-based payment arrangement [line items] Non-current liabilities Non-current liabilities [abstract] Provision for attendance fees Provision For Attendance Fees The amount of provision for attendance fees. Short-term investments, variation of fair value through the consolidated statement of income (loss) Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on current financial assets at fair value through profit or loss. Non-current contract liabilities at the beginning of period Non-current contract liabilities s at end of period Non-current contract liabilities Disclosure of detailed information about financial instruments [table] Disclosure of detailed information about financial instruments [table] Agreements with Genzyme for NK Cell engages Agreements with Genzyme for NK Cell engages [Member] Agreements with Genzyme for NK Cell engages Deferred revenue - current and non-current portion Deferred income including contract liabilities Revenue and other income Disclosure of revenue [text block] Document Fiscal Year Focus Document Fiscal Year Focus Significant Accounting Policies [Abstract] Trade receivables and others Receivables and others - current Trade and other current receivables Novo Nordisk A/S Novo Nordisk A/S [Member] This member stands for Novo Nordisk A/S. Unused tax losses with no expiration date Unused Tax Losses With No Expiration Date The amount of unused tax losses with no expiration date. AGA New members 2023-1 AGA New Members 2023-1 [Member] AGA New Members 2023-1 Statement Line Items [Line Items] Disclosure of maturity analysis for non-derivative financial liabilities [line items] Number of own shares (in shares) Number of shares in entity held by entity or by its subsidiaries or associates Total, foreign currency effect Total, Foreign Currency Effect The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements. Financial liabilities – current portion Current financial liabilities Disclosure of detailed information about financial instruments Disclosure of detailed information about financial instruments [text block] AGA Perf Employees 2024-1 AGA Perf Employees 2024-1 [Member] AGA Perf Employees 2024-1 AGA Perf Employees 2023-1 AGA Perf Employees 2023-1 [Member] AGA Perf Employees 2023-1 Agreement with Sanofi, 2022 Sanofi Research Collaboration And Licensing Agreement [Member] Sanofi Research Collaboration And Licensing Agreement Financial expenses Financial expenses Finance costs Cash, cash equivalents, short-term investments and non-current financial assets Disclosure of financial assets [text block] Types of interest rates Types of interest rates [domain] Upfront payment, commitment Upfront Payment Commitment Upfront Payment Commitment Other income Other income Classes of other provisions [axis] Classes of other provisions [axis] BSA 2025-1 BSA 2025-1 [Member] BSA 2025-1 Share Capital and Share Base Payments [Abstract] Basis of presentation and statement of compliance Disclosure of material accounting policy information [text block] Cash and cash equivalents Financial Assets, Cash And Cash Equivalents [Member] Financial Assets, Cash And Cash Equivalents Recently issued accounting standards and interpretations Disclosure of expected impact of initial application of new standards or interpretations [text block] Foreign exchange gains Foreign exchange gain Suppliers (excluding payables related to capital expenditures) Current trade payables Executive Board Members and other Executive Members compensation Key management personnel compensation Entity Central Index Key Entity Central Index Key Non-current financial assets, variation of fair value through the consolidated statement of income (loss) Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on non-current financial assets at fair value through profit or loss. Unrealized losses on financial assets Unrealized Losses On Financial Assets The amount of unrealized losses on financial assets. Characteristics of defined benefit plans [axis] Characteristics of defined benefit plans [axis] Disclosure of defined benefit plans Disclosure of defined benefit plans [text block] Reclassification Reclassification, Non Current Contract Liabilities Reclassification, Non Current Contract Liabilities Statement Table [Table] Disclosure of maturity analysis for non-derivative financial liabilities [table] Ordinary Shares Ordinary shares [member] Trade account receivables Current trade receivables Disclosure of reconciliation of changes in short-term investments and non-current financial assets Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block] Income / (loss) per share Disclosure of earnings per share [text block] Beginning balance, total Ending balance, total Short-term Investments And Non-current Financial Assets The amount of short-term investments and non-current financial assets. Trade payables and others Payables and others Trade and other current payables Liabilities Equity and liabilities [abstract] Applicable tax rate Applicable tax rate Proceeds from collaboration and licensing agreements Collaboration And Licensing Agreements [Member] This member stands for collaboration and licensing agreements. Reconciliation of changes in property, plant and equipment [abstract] Reconciliation of changes in property, plant and equipment [abstract] Proceeds from the exercise / subscription of equity instruments Proceeds from issuing shares Within 1 year Not later than one year [member] Number of collaboration contracts Number Of Collaboration Contracts Number Of Collaboration Contracts Number of subsidiaries Number Of Wholly Owned Subsidiaries Number Of Wholly Owned Subsidiaries Average rate (€1 equals to USD) Average foreign exchange rate BSAAR 2011 BSAAR 2011 [Member] This member stands for BSAAR 2011. Proceeds Increase Through Upfront Payment, Contract Liabilities The increase in contract liabilities resulting from upfront payment. Operating income (loss) Profit (loss) from operating activities AGAP Perf Management 2018-1 AGAP Perf Management 2018-1 [Member] This member stands for AGA Perf Management 2018-1. Other receivables Other current receivables Financial liabilities at fair value through profit or loss, category Financial liabilities at fair value through profit or loss, category [member] Borrowing – Equipment Loan, Equipment [Member] This member stands for loan, equipment. Disclosure of financial assets [Line Items] Disclosure of financial assets [line items] Tax Credit Retentions 2024, CIR Tax Credit Retentions 2024, CIR Tax Credit Retentions 2024, CIR Proceeds from borrowing Proceeds from borrowings, classified as financing activities Trade receivables and others Trade Receivables And Others [Member] This member stands for trade receivables and others. Scientific advisory and consulting Scientific Advisory And Consulting The amount of Scientific advisory and consulting. Employee benefits costs Adjustments for increase (decrease) in employee benefit liabilities Other profit or loss items with no cash effect Other adjustments to reconcile profit (loss) Sanofi (2022) services Sanofi, Services [Member] Sanofi, Services Entity Registrant Name Entity Registrant Name Basic income (loss) per share (in EUR per share) Basic earnings (loss) per share Revenue for the six months period Recognition in P&L Decrease through performance obligation being satisfied, contract liabilities Foreign exchange (gains) losses on financial assets Adjustments for unrealised foreign exchange losses (gains) Government financing for research expenditures Government financing for research expenditures Government Financing For Research Expenditures The amount of income recognised in relation to government financing for research expenditures. Deferred revenue - current and non-current portion, variance Adjustments for increase (decrease) in deferred income including contract liabilities Provision for expenses with related parties Provision For Expenses With Related Parties Provision For Expenses With Related Parties BSAAR 2012 BSAAR 2012 [Member] This member stands for BSAAR 2012. Additions Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Clinical Services Clinical Services [Member] Clinical Services Collaboration liabilities - current and non-current portion, variance Adjustments For Increase (Decrease) In Collaboration Liabilities Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)] Collaboration liabilities - current and non-current portion Collaboration Liabilities The amount of collaboration liabilities. Statement of cash flows [abstract] Weighted average number of shares, diluted (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Foreign exchange impact Foreign Exchange Gain (Loss), Contract Liabilities Foreign Exchange Gain (Loss), Contract Liabilities Disclosure of financial assets [Table] Disclosure of financial assets [table] Change in accrued interests on financial assets Adjustments for decrease (increase) in accrued income including contract assets Agreement with Sanofi, 2022 - ANKET IPH62 Agreement With Sanofi 2022 - ANKET IPH62 [Member] Agreement With Sanofi 2022 - ANKET IPH62 Number of other equity instruments exercisable in share-based payment arrangement (in shares) Number of other equity instruments exercisable in share-based payment arrangement BSA 2014 BSA 2014 [Member] This member stands for BSA 2014. Share-based compensation expense Adjustments for share-based payments Lease liabilities - Printers Lease Financing Obligations, Printers [Member] Lease Financing Obligations, Printers Total variance of accrued interest Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss. Number of therapeutic approaches Number Of Therapeutic Approaches Number Of Therapeutic Approaches Estimated financial effect of contingent liabilities Estimated financial effect of contingent liabilities Current Current contract liabilities [abstract] Financial liabilities—non-current portion Financial Liabilities, Non-current Portion [Member] This member stands for financial liabilities—non-current portion. AstraZeneca AstraZeneca [Member] AstraZeneca AGA "Plan Epargne Entreprise" 2023 AGA "Plan Epargne Entreprise" 2023 [Member] AGA "Plan Epargne Entreprise" 2023 Types of financial assets [axis] Types of financial assets [axis] Deferred tax assets / Provision for defined benefit obligation Provision for defined benefit obligation [Member] Provision for defined benefit obligation Advance received Revenue From Contracts With Customers, Advance Payment Received The amount of advance received by the company. Extra pension benefits Key Management Personnel Compensation, Extra Pension Benefits Key Management Personnel Compensation, Extra Pension Benefits Current liabilities Current liabilities [abstract] Disclosure Of Income Tax [Line Items] Disclosure Of Income Tax [Line Items] Disclosure Of Income Tax [Line Items] Warrants Warrants [member] Employee benefit Disclosure of employee benefits [text block] Characteristics of defined benefit plans Characteristics of defined benefit plans [domain] AGAP 2019 Employees 2019 AGAP 2019 Employees 2019 [Member] Related to the plan. Shareholders’ equity Equity [abstract] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of detailed information about financial instruments [abstract] Deferred tax liabilities / Deferred revenue Deferred Revenue [Member] This member stands for deferred revenue. Disclosure of transactions between related parties [Line Items] Disclosure of transactions between related parties [line items] Loan agreement, maximum borrowing capacity Loan Agreement Maximum Borrowing Capacity Maximum borrowing capacity under the loan agreement. Prepayments made to suppliers Non-current prepayments Lease liabilities – Laboratory equipment Lease Financing Obligations, Equipment [Member] This member stands for lease finance obligations, equipment. AGAP 2019 Management 2019 AGAP 2019 Management 2019 [Member] Related to the plan. Subclassifications of assets, liabilities and equities [abstract] Disclosure of nature and extent of risks arising from financial instruments [abstract] Classes of share capital [domain] Classes of share capital [domain] State guaranteed loan, Societe Generale and BNP Paribas PGE Loan Agreement, Societe Generale And BNP Paribas [Member] PGE Loan Agreement, Societe Generale And BNP Paribas Proceeds from issue of ordinary shares Proceeds from issue of ordinary shares Reclassification Reclassification, Contract Liabilities Reclassification, Contract Liabilities Financial income Financial income Finance income Classes of financial liabilities [axis] Classes of financial liabilities [axis] Agreement With Sanofi 2022 - ANKET IPH67 Agreement With Sanofi 2022 - ANKET IPH67 [Member] Agreement With Sanofi 2022 - ANKET IPH67 Classes of financial liabilities [domain] Classes of financial liabilities [domain] Payments (benefits and contributions paid by the employer) Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer Commitments, Contingencies And Litigations [Abstract] Commitments, Contingencies And Litigations [Abstract] Commitments, Contingencies And Litigations Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Restructuring provision Restructuring provision [member] Types of contracts [axis] Types of contracts [axis] Share premium Share premium [member] Provisions - non-current portion Non-current provisions Actuarial assumption of discount rates Actuarial assumption of discount rates Disclosure of revenue from collaboration and licensing agreements Disclosure of disaggregation of revenue from contracts with customers [text block] Disclosure of key management personnel compensation Disclosure Of Key Management Personnel Compensation [Table Text Block] The disclosure for key management personnel compensation. Financial covenant minimum financial assets threshold Financial Covenant Minimum Financial Assets Threshold Financial Covenant Minimum Financial Assets Threshold Disposal of current financial instruments and paid interests Disposal Of Current Financial Instruments And Paid Interests, Classified As Investing Activities Disposal Of Current Financial Instruments And Paid Interests, Classified As Investing Activities BSA 2011-2 BSA 2011-2 [Member] Related to the plan. AGA Management 2016-2 AGA Management 2016-2 [Member] This member stands for AGA Management 2016-2. AGAP Employees 2016-1 AGAP Employees 2016-1 [Member] This member stands for AGAP Employees 2016-1. Total, variation of fair value through the consolidated statement of income (loss) Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss. Financial assets pledged as collateral for liabilities or contingent liabilities Financial assets pledged as collateral for liabilities or contingent liabilities Minimum Minimum [Member] Disclosure of number and weighted average exercise prices of other equity instruments Disclosure of number and weighted average exercise prices of other equity instruments [text block] Agreements with Sanofi for NK Cell engages Agreements with Sanofi for NK Cell engages [Member] Agreements with Sanofi for NK Cell engages AGA 2025-01 AGA 2025-01 [Member] AGA 2025-01 Share capital Issued capital BSA 2015-2 BSA 2015-2 [Member] This member stands for BSA 2015-2. AGA Employees 2017 AGA Employees 2017 [Member] This member stands for AGA Employees 2017. Income Tax [Abstract] Income Tax [Abstract] Type Of Employee [Axis] Type Of Employee [Axis] Type Of Employee Non-current financial assets, disposals Decrease Through Derecognition Non-current Financial Assets The decrease in non-current financial assets resulting from derecognition. State guaranteed loans - accrued interest PGE Loan Agreement, Accrued Interest [Member] PGE Loan Agreement, Accrued Interest AGA Perf Employees 2022-1 AGA Perf Employees 2022-1 [Member] AGA Perf Employees 2022-1 Categories of financial assets [axis] Categories of financial assets [axis] State guaranteed loan Société Générale PGE Loan Agreement, Societe Generale [Member] PGE Loan Agreement, Societe Generale AGA Perf Employees 2025-1 AGA Perf Employees 2025-1 [Member] AGA Perf Employees 2025-1 Number of shares outstanding (in shares) Number of shares outstanding Products and services [axis] Products and services [axis] Other temporary differences Other temporary differences [member] Financial liabilities Financial liabilities Total change in Working Capital Change In Working Capital The amount of working capital. Income tax expense Tax expense (income) Deferred revenue – non-current portion Non-current deferred income including non-current contract liabilities Deferred revenue – current portion Current deferred income including current contract liabilities Deferred Tax liabilities Deferred Tax Liabilities, Offset Amount Deferred Tax Liabilities, Offset Amount Events after the reporting date Disclosure of events after reporting period [text block] Disclosure of information about defined benefit plans [abstract] Number of employees Number of employees Number of exclusive options granted Number Of Exclusive Options Granted Number Of Exclusive Options Granted Trade receivables and others Trade and other receivables IPH5201 agreement, with AstraZeneca 2018 AstraZeneca IPH5201 Agreement [Member] This member stands for Agreement related to IPH5201 with AstraZeneca. Guarantees Guarantees [member] Number of loans Number Of Loans Number Of Loans Disclosure of net financial income (loss) Disclosure Of Net Financial Income (Loss) [Table Text Block] The disclosure of net financial income (loss). Property and equipment Property, plant and equipment including right-of-use assets at beginning of period Property, plant and equipment including right-of-use assets at end of period Property, plant and equipment including right-of-use assets Disclosure of defined benefit plans [line items] Disclosure of defined benefit plans [line items] Document Period End Date Document Period End Date Current tax expense (income) Current tax expense (income) Administration Administration [Member] Administration Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] Transfer from / (to) collaboration liabilities Transfer From (To) Collaboration Liabilities The decrease in contract liabilities resulting from transfer to collaboration liabilities. Non-adjusting events after reporting period Non-adjusting events after reporting period [domain] Disclosure of changes in the share capital Disclosure of classes of share capital [line items] Disclosure of effect of changes in foreign exchange rates Disclosure of effect of changes in foreign exchange rates [text block] Maturity [axis] Maturity [axis] Research and development expenses Research and development expense Scenario [Axis] Scenario [Axis] Revenue for the six months period Decrease Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Decrease Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Total Total Short-Term Investments And Non-Current Financial Assets [Abstract] Total Short-Term Investments And Non-Current Financial Assets Legal proceedings provision Legal proceedings provision [member] From 3th to 4th year included Later than three years and not later than four years [member] Actuarial gains and (losses) related to defined benefit obligations Actuarial gains (losses) on defined benefit obligations Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Document Type Document Type Share-based compensation Expense from share-based payment transactions with employees Classes of financial assets [axis] Classes of financial assets [axis] Payments for research work Revenue From Contracts With Customers, Advance Payment Received, Research Revenue From Contracts With Customers, Advance Payment Received, Research Current contract liabilities at the beginning of period Current contract liabilities at end of period Current contract liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Deductions Decrease Through Repayments, Non Current Contract Liabilities Decrease Through Repayments, Non Current Contract Liabilities AGA Management 2025 AGA Management 2025 [Member] AGA Management 2025 Lease liabilities – Vehicles Lease Financing Obligations, Vehicles [Member] Related to the lease financing obligation for vehicles. Provisions - current portion Current provisions From 4th to 5th year included Later than four years and not later than five years [member] Borrowings by name Borrowings by name [domain] Types of share-based payment arrangements [domain] Types of share-based payment arrangements [domain] Defined benefit obligations Defined benefit obligation, at present value Reclassification Reclassification, Current Contract Liabilities Reclassification, Current Contract Liabilities Proceeds from lease liabilities and other non cash effects Proceeds From Lease Liabilities, Classified As Financing Activities The amount of proceeds from lease liabilities. Interest received on financial assets Interest Received Adjustment, Classified As Investing Activities Interest Received Adjustment, Classified As Investing Activities Deferred tax assets / Tax losses carryforwards - France FRANCE Revenue from collaboration and licensing agreements Revenue from contracts with customers Net income (loss) per share : Earnings per share [abstract] Range [axis] Range [axis] Interests and gain on financial assets Interests And Gains On Financial Assets The amount of interests and gains on financial assets. Components of equity [axis] Components of equity [axis] Fixed interest rate Fixed interest rate [member] Financial liabilities Disclosure of financial liabilities [text block] Disclosure of financial liabilities [Line Items] Disclosure of financial liabilities [line items] Geographical [Axis] Geographical [Axis] Non-Current Non-current contract liabilities [abstract] Net income (loss) before tax Profit (loss) before tax Property, plant and equipment including right-of-use assets [axis] Property, plant and equipment including right-of-use assets [axis] Other comprehensive income (loss) Other comprehensive income Classes of liabilities [axis] Classes of liabilities [axis] Laboratory equipment and other Laboratory Equipment And Other [Member] This member stands for laboratory equipment and other. Disclosure of operating expenses [Line Items] Disclosure of operating expenses [Line Items] Disclosure of operating expenses [Line Items] Treasury shares Treasury shares [member] Monalizumab agreement (AstraZeneca) Monalizumab agreement Monalizumab Agreement [Member] This member stands for monalizumab agreement. Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Depreciation and amortization, net Adjustments for depreciation and amortisation expense Forecast Forecast [Member] Payables related to capital expenditures Current Payables Related To Capital Expenditures The amount of current payables related to capital expenditures. Advisory fees Key Management Personnel Compensation, Advisory Fees Key Management Personnel Compensation, Advisory Fees Collaboration liabilities – non-current portion Collaboration Liabilities, Non-current The amount of non-current collaboration liabilities. Categories of related parties Categories of related parties [domain] Pledged collateral margin percentage Pledged Collateral Margin Percentage Pledged Collateral Margin Percentage Research tax credit Non-Current Research Tax Credit The amount of non-current research tax credit. Net Capital Increase Issue of equity Issue of equity Total, disposals Decrease Through Derecognition Short-term Investment And Non-current Financial Assets The decrease in short-term investment and non-current financial assets resulting from derecognition. Undiscounted cash flows Bank borrowings, undiscounted cash flows Disclosure of disaggregation of revenue from contracts with customers [abstract] Stock Options 2024-1 Stock Options 2024-1 [Member] Stock Options 2024-1 AGA employees 2024-1 AGA Employees 2024-1 [Member] AGA Employees 2024-1 Net defined benefit asset Net defined benefit asset Short-term investments Short Term Investments1 [Abstract] Short Term Investments1 Collection Cash advances and loans from related parties Payments for target options Revenue From Contracts With Customers, Advance Payment Received, Target Options Revenue From Contracts With Customers, Advance Payment Received, Target Options Disclosure of trade payables and others Disclosure Of Trade Payables And Others [Text Block] The disclosure of trade payables and others. Foreign exchange variation Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement Monalizumab Monalizumab [Member] This member stands for Monalizumab. Type Of Employee [Domain] Type Of Employee [Domain] Type Of Employee [Domain] Interest received Interest received, classified as operating activities Short-term investments, variation of accrued interest Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss The amount of income arising from interest for current financial assets that are not at fair value through profit or loss. Trade receivables and others - non-current Receivables and others - non-current Trade and other non-current receivables Attribution of expenses by nature to their function Attribution of expenses by nature to their function [domain] Cash, cash equivalents, and financial assets denominated in US dollars Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member] Related to cash, cash equivalents, and financial assets denominated in US dollars. Deferred Tax assets Deferred Tax Assets, Offset Amount Deferred Tax Assets, Offset Amount Depreciation Depreciation Depreciation, property, plant and equipment including right-of-use assets Products and services Products and services [domain] Capital Disclosure of issued capital [text block] Sanofi (2022) option Sanofi, Options [Member] Sanofi, Options Property, plant and equipment including right-of-use assets [domain] Property, plant and equipment including right-of-use assets [domain] Repayment of borrowings Repayments of borrowings, classified as financing activities Weighted average number of shares, basic (in shares) Weighted average number of ordinary shares in circulation (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share BSA 2017 BSA 2017 [Member] This member stands for BSA 2017. Short-term investments, foreign currency effect Short-term Investments, Foreign Currency Effect The increase (decrease) in current financial assets resulting from foreign exchange and other movements. Borrowings by name [axis] Borrowings by name [axis] Short-term investments Short-term investments Current financial assets Lease liabilities – Premises Innate Inc. Lease Financing Obligations, Innate Inc. Premises [Member] Related to the lease financing obligations for the Innate Inc. premises. AGAP Employees 2017-1 AGAP Employees 2017-1 [Member] Related to a plan. Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Trade payables and others Disclosure of trade and other payables [text block] Borrowing, grace period Borrowing, Grace Period Borrowing, Grace Period Prepayments made to suppliers Current advances to suppliers Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Non-current financial assets, variation of accrued interest Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss. Other reserves Other reserves Share-based compensation Key management personnel compensation, share-based payment AGAP Management 2016-2 AGAP Management 2016-2 [Member] This member stands for AGAP Management 2016-2. Travel expenses and meeting attendance Travel expense Allowance for seniority awards Seniority Awards [Member] This member stands for seniority awards. Disclosure of expenses by nature Disclosure of expenses by nature [text block] Deferred tax assets / Tax amortization Tax Amortization [Member] Tax Amortization Deductions Decrease Through Repayments, Contract Liabilities The decrease in contract liabilities resulting from deductions. Net income (loss) Retained earnings, profit (loss) for reporting period [member] Commitments, contingencies and litigation Disclosure of commitments and contingent liabilities [text block] Financial instruments recognized in the statement of financial position and related effect on the income statement Disclosure of financial instruments [text block] Financial liabilities, fair value Financial Liabilities, Trade Payables And Others, At Fair Value The fair value of financial liabilities, trade payables and other. AGA Management 2024-1 AGA Management 2024-1 [Member] AGA Management 2024-1 Trade receivables and others - current and non-current portion (excluding receivables related to Property & equipment) Trade And Other Receivables, Excluding Receivables Related To Property & Equipment Trade And Other Receivables, Excluding Receivables Related To Property & Equipment Disclosure of detailed information about property, plant and equipment Disclosure of detailed information about property, plant and equipment [text block] Borrowings, interest rate Borrowings, interest rate Net cash generated from / (used in) investing activities: Cash flows from (used in) investing activities Net increase / (decrease) in cash and cash equivalents: Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Payments Cash advances and loans made to related parties Withholding rate CIR Withholding Rate, CIR Withholding Rate, CIR Transfer from / (to) collaboration liabilities Transfer To (From) Collaboration Liabilities The decrease in contract liabilities resulting from transfer to collaboration liabilities. Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Net cash generated / (used in) from financing activities: Cash flows from (used in) financing activities Additions Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities Short-term investments, disposals Decrease Through Derecognition Short-term Investment The decrease in current investment resulting from derecognition. Non-current financial assets Beginning balance, non-current financial assets Ending balance, non-current financial assets Non-current financial assets Personnel expenses Employee benefits expense Percentage of prefinanced CIR collected Percentage Of Pre Financed CIR Collected 2023 And 2024 Percentage Of Pre Financed CIR Collected 2023 And 2024 Preferred Shares Preference shares [member] Research tax credit Research Tax Credit, Receivable, Current Research Tax Credit, Receivable, Current Disclosure of trade payables and others [Table] Disclosure of trade payables and others [Table] Disclosure of trade payables and others [Table] Loan agreement with Société Générale Loan Agreement With Société Générale [Member] This member stands for loan agreement with Société Générale. Management of financial risks Disclosure of nature and extent of risks arising from financial instruments [text block] The Company and key events Disclosure Of Company, Significant Agreements And Key Events [Text Block] Disclosure Of Company, Significant Agreements And Key Events Change in working capital Total change in working capital, variance Increase (decrease) in working capital Total current assets Current assets Collaboration liabilities Collaboration Liabilities [Member] This member stands for collaboration liabilities. Disclosure of operating segments [Table] Disclosure of operating segments [table] Statement of changes in equity [table] Statement of changes in equity [table] AGA Perf Management 2024-1 AGA Perf Management 2024-1 [Member] AGA Perf Management 2024-1 Retained earnings Retained earnings, excluding profit (loss) for reporting period [member] Operating cash flow before change in working capital Cash flows from (used in) operations before changes in working capital Disclosure of cash, cash equivalents and financial assets Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block] The disclosure of cash, cash equivalents and financial assets. Borrowing – Building Loan, Building [Member] This member stands for loan, building. Current borrowings and current portion of non-current borrowings Current borrowings and current portion of non-current borrowings Current Fiscal Year End Date Current Fiscal Year End Date Disposal of property and equipment Proceeds from sales of property, plant and equipment, classified as investing activities Disclosure of government financing for research expenditures Disclosure Of Government Financing For Research Expenditures [Table Text Block] The disclosure of government financing for research expenditures. Employer contribution rate on share based payments Employer Contribution Rate On Share Based Payments Employer Contribution Rate On Share Based Payments Disclosure of transactions between related parties [Table] Disclosure of transactions between related parties [table] AGA Bonus 2020-1 & 2 AGA Bonus 2020-1 & 2 [Member] AGA Bonus 2020-1 & 2 Short-term investments, acquisitions Short-term Investments, Acquisitions The increase in current investment resulting from origination or purchase. Other tax credits Other Current Tax Credits Receivables The amount of other current tax credits receivables. Change in fair value of financial assets Adjustments for fair value losses (gains) Profit (loss) [abstract] Categories of related parties [axis] Categories of related parties [axis] Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] Financial liabilities at amortised cost, category Financial liabilities at amortised cost, category [member] Financial assets at amortised cost, category Financial assets at amortised cost, category [member] AGA Perf Management 2024-2 AGA Perf Management 2024-2 [Member] AGA Perf Management 2024-2 Disposal of other assets Proceeds from sales of other long-term assets, classified as investing activities Par value per share (in EUR per share) Par value per share Disclosure of non-adjusting events after reporting period [table] Disclosure of non-adjusting events after reporting period [table] Property and equipment Disclosure of property, plant and equipment [text block] Net income (loss) Net income (loss) for the period: Net income (loss) Net loss for the period Profit (loss) Security interest on pledge of financial instruments released in 2024 including interest Security Interest On Pledged Financial Instruments Released, Including Interest Security Interest On Pledged Financial Instruments Released, Including Interest BSA 2023-1 BSA 2023-1 [Member] BSA 2023-1 Financial assets Financial assets Amendment Flag Amendment Flag IPH5201 agreement, with AstraZeneca Invoicing Research And Development Costs IPH5201 [Member] Invoicing Research And Development Costs IPH5201 Components of equity [domain] Components of equity [domain] Total non-current liabilities Non-current liabilities Statement Line Items [Line Items] Disclosure of operating segments [line items] Borrowing, percentage of state-guaranteed loan Borrowing, Percentage Of State-Guaranteed Loan Borrowing, Percentage Of State-Guaranteed Loan Closing rate (€1 equals to USD) Closing foreign exchange rate AGAP Management 2016-1 AGAP Management 2016-1 [Member] This member stands for AGAP Management 2016-1. AGA 2025-02 AGA 2025-02 [Member] AGA 2025-02 Non-current financial assets, foreign currency effect Non-current Financial Assets, Foreign Currency Effect The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements. Balance at beginning of period (in shares) Balance at end of period (in shares) Number of shares issued (in shares) Total number of shares issued (in shares) Number of shares issued Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [domain] Temporary difference, unused tax losses and unused tax credits [domain] Ranges [member] Range [domain] Trade payables and others Trade Payables And Others [Member] This member stands for trade payables and others. Change in working capital Summary Of Changes In Working Capital [Abstract] Summary Of Changes In Working Capital Disposal of property and equipment (scrapping) Adjustments for gain (loss) on disposals, property, plant and equipment Net financial income / (loss) Disclosure of finance income (cost) [text block] Trade payables and others (excluding payables related to capital expenditures), variance Adjustments for increase (decrease) in trade and other payables The 2017 free preferred shares The 2017 Free Preferred Shares [Member] Related to the 2017 free preferred shares. From 1st to 2nd year included Later than one year and not later than two years [member] Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Revenue for the six months period Decrease Through Performance Obligation Being Satisfied, Current Contract Liabilities Decrease Through Performance Obligation Being Satisfied, Current Contract Liabilities AGAP Management 2021-1 AGAP Management 2021-1 [Member] AGAP Management 2021-1 AGAP Perf Employees 2018-1 AGAP Perf Employees 2018-1 [Member] Related to the plan. Scenario [Domain] Scenario [Domain] AGA "Plan Epargne Entreprise" 2024 AGA "Plan Epargne Entreprise" 2024 [Member] AGA "Plan Epargne Entreprise" 2024 Analysis of income and expense [abstract] Analysis of income and expense [abstract] Amounts payable, related party transactions Liabilities Amounts payable, related party transactions Depreciation and amortization Depreciation and amortisation expense AGA Bonus 2018-1 AGA Bonus 2018-1 [Member] Related to the plan. Financial liabilities – non-current portion Non-current financial liabilities Milestone payment received Revenue From Contracts With Customers, Milestone Payment Received Revenue From Contracts With Customers, Milestone Payment Received Foreign exchange impact Foreign Exchange Gain (Loss), Non Current Contract Liabilities Foreign Exchange Gain (Loss), Non Current Contract Liabilities Categories of financial assets Categories of financial assets [domain] Strategic partnership with Swedish Orphan Biovitrum AB Strategic Partnership With Swedish Orphan Biovitrum AB [Member] Strategic Partnership With Swedish Orphan Biovitrum AB Transfers Increase (decrease) through transfers from construction in progress, property, plant and equipment including right-of-use assets Decrease in revenue from contracts with customers Increase (Decrease) In Revenue From Contracts With Customers Increase (Decrease) In Revenue From Contracts With Customers Notional amount Notional amount Changes in equity [abstract] Changes in equity [abstract] Personnel and other short-term employee benefits Key management personnel compensation, short-term employee benefits Number of licensing agreements Number Of Licensing Agreements With Related Parties Number Of Licensing Agreements With Related Parties Net defined benefit liability (asset) at beginning of period Net defined benefit liability (asset) at end of period Net defined benefit liability (asset) Foreign exchange impact Foreign Exchange Gain (Loss), Current Contract Liabilities Foreign exchange gain (loss), Current Contract Liabilities Diluted income (loss) per share (in EUR per share) Diluted income/(loss) per share (in EUR per share) Diluted earnings (loss) per share Maturity [domain] Maturity [domain] Defined benefit obligations Non-current provisions for employee benefits Categories of financial liabilities [axis] Categories of financial liabilities [axis] Disclosure of terms and conditions of share-based payment arrangement [Table] Disclosure of terms and conditions of share-based payment arrangement [table] Intellectual property expenses Intellectual Property Expenses The amount of intellectual property expenses. Tax and employee-related payables Payables on social security and taxes other than income tax Beginning balance, current investments Ending balance, current investments Current investments AGA "Plan Epargne Entreprise" 2022 AGA "Plan Epargne Entreprise" 2022 [Member] AGA "Plan Epargne Entreprise" 2022 Summary of income (loss) per share Earnings per share [text block] Increase capital, net (In Shares) Increase Capital, Net (In Shares) Increase Capital, Net (In Shares) Intangible assets other than goodwill [abstract] Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Borrowings, maturity period Borrowings, Maturity Period Borrowings, Maturity Period Disclosure of trade payables and others [Line Items] Disclosure of trade payables and others [Line Items] Disclosure of trade payables and others [Line Items] Leasing and maintenance Leasing And Maintenance The amount of leasing and maintenance.